In addition to its current offerings, Avedro is dedicated to developing the science of Thermo-biomechanics for therapeutic medical applications. The Keraflex® refractive correction procedure, the first technology developed from the Thermo-biomechanics platform, is a non-invasive ophthalmic procedure for flattening the cornea, which is commercially available outside the United States. It provides a unique ability to induce refractive change without compromising the cornea’s biomechanical integrity, setting it apart from traditional refractive correction procedures such as Lasik.
Founded in 2007, Avedro has received significant backing, with its most recent Series F investment totaling $25.00M received on 02 May 2018. The investment came from a consortium of notable investors including HealthQuest Capital, InterWest Partners, Lilly Asia Ventures, OrbiMed, and DeNovo Ventures.
Avedro's focus on innovative technology and its successful fundraising efforts position the company as a promising player in the Health Care, Medical Devices, and Pharmaceutical industries.
